



ECNP Research & Scholarship
Foundation (R&S)
Annual Report
and Policy Plan

2014

R&S is a public-interest-serving entity
(algemeen nut beogende instelling – ANBI)
under Dutch tax law

Contents

- 1. Mission 3
 - What Is the ECNP Research and Scholarship Foundation 3
 - The board of R&S..... 4

- 2. Governance 4
 - The Board 4
 - Sub-Committees and Task Forces 4
 - Office 5

- 3. Funding 6
 - R&S Funding Model 6
 - Financial Management 6
 - Asset Management 6

- 4. Current Activities 7
 - Developing young researchers 7
 - Building research infrastructure..... 8
 - Fostering common regional standards..... 10

- 5. Forward Strategy 12
 - Risk Management and Long-Term Financial Strategy 12
 - Future Spending Plans..... 12

- 6. Finances 15
 - Balance sheet as at 31 December 2014 15
 - Profit and loss account 2014 16

1. Mission

What Is the ECNP Research and Scholarship Foundation

The ECNP Research and Scholarship Foundation (R&S) is a non-profit foundation constituted under Dutch law and domiciled in Utrecht, the Netherlands.

Founded in 1995, the objective of R&S is to promote research in the field of applied and translational neuroscience, and to create a framework in conjunction with the European College of Neuropsychopharmacology (ECNP) for scientific and educational initiatives and activities.

It does this by organising a variety of educational meetings that aim to identify and cultivate especially promising European junior scientists and clinicians and assist them in improving their research output and clinical effectiveness. Every year some 300 young scientists and clinicians pass through R&S programmes, funded by the foundation. In addition, R&S organises various projects designed to develop and enhance the research infrastructure for European applied and translational neuroscience.

R&S is a public-interest-serving foundation (Algemeen Nut Beogende Instelling) under Dutch law.

Our mission:

“To advance the science of the brain, promote better treatment, and enhance brain health.”

Contact details

ECNP Research and Scholarship Stichting
Bolognalaan 28
3584 CJ Utrecht
Tel: +31 88 756 9555
E-mail: secretariat@ecnp.eu
Website: www.ecnp.eu

Key identification numbers

VAT number: NL807967087B01

Tax identification number (RSIN): 807967087

Chamber of Commerce number: 41215196

2. Governance

The Board

The R&S board is responsible for administering the foundation and conducting all acts of management and decision-making. The board comprises a chair, a treasurer and a secretary.

Board members serve on a voluntary basis. Expenses directly related to their R&S board activities are reimbursed at cost, but board members receive no further recompense.

Members of the board



Guy Goodwin
Chair

Professor of Psychiatry
University of Oxford
United Kingdom



Eduard Vieta
Treasurer

Professor of Psychiatry
University of Barcelona
Spain



Celso Arango
Secretary

Professor of Psychiatry
Hospital General Universitario Gregorio Marañón
Madrid, Spain

Sub-Committees and Task Forces

R&S oversees a number committees and task forces staffed by scientists active in the field of applied and translational neuroscience.

- **Educational Committee**, to oversee ECNP's training activities and educational programmes, especially for junior scientists.
- **Workshop Committee**, to co-ordinate the programme design and organisation of the annual ECNP Workshop on for Junior Scientists in Europe, held annually in Nice, France.

- **Nomenclature Task Force**, to spearhead the project, led by ECNP, to rationalise the naming conventions of psychotropic medications.

The members of the board and all R&S sub-committees work on a volunteer basis. R&S reimburses travel and accommodation costs, but does not remunerate for time invested.

Office

For administrative and logistical support, R&S uses the ECNP Office, based in Utrecht, the Netherlands. The ECNP Office is charged with the day-to-day management of R&S activities and the administration of its funds and resources. Specific functions include:


- Implementing decisions of the board;
- Organising all R&S meetings, programmes and activities;
- Providing the scientific secretariat of R&S meetings;
- Administering R&S finances;
- Conducting all day-to-day communication on behalf of R&S.

The operating expenses of the ECNP Office relative to R&S activities are charged to the foundation at cost.

3. Funding

R&S Funding Model

The funds of R&S are derived, in principle, from lump-sum or periodic contributions, grants, donations, legacies or other revenue. In practice, this means the surplus of the annual ECNP Congress.



Financial Management

The R&S board is responsible for the financial management of R&S's funds. Professional auditors are appointed by the board for a term of office of two years, at the expiration of which they will be re-eligible. The auditors control and verify the inventory and accounts, the book-keeping and the funds of the ECNP. They report to the board in writing about the balance sheet and the result of their auditing. The external auditor is currently Schuiteman & Partners Registeraccountants B.V.

Asset Management

The main part of R&S's capital is invested in portfolios managed by a Dutch bank. Oversight of these portfolios is, in the first instance, the responsibility of the ECNP Office, reporting to the Treasurer. R&S has a 'defensive' investment mandate, designed to avoid risk and deliver a steady rate of return, with an asset allocation accordingly weighted heavily towards fixed-income securities.

4. Current Activities

R&S's activities are organised according to a number of priority themes:

Developing young researchers

- **ECNP Workshop** – three-day intensive educational session for 100 junior scientists, competitively selected, held annually in Nice, France. For those selected no registration fee is charged and the travel and accommodation are substantially covered by R&S.



By promoting and encouraging the development of junior scientists seeking to pursue research careers in neuropsychopharmacology, the ECNP Workshop aims to stimulate high-quality experimental and clinical research in disorders of the brain and their treatments. The Workshop focuses on three recurring topics and one variable topic, within each of which two distinguished scientists address specific themes, followed by short presentations of their research by five junior scientists.

- **ECNP Schools** – a week-long programme of intensive training in all aspects of neuropsychopharmacology for exceptional young clinicians. Participants are nominated by members of the ECNP Advisory Board of National Societies or ECNP Ambassadors, with two to three potential candidates per country, on the basis of their career potential. Travel and accommodation costs are substantially covered by R&S. So far three Schools have been established:



- ECNP School on Neuropsychopharmacology – annual
- ECNP School on Child and Adolescent Neuropsychopharmacology – annual
- ECNP School on Old Age Neuropsychopharmacology – biennial

New in 2014

The 2014 **ECNP Workshop** was held on 6-9 March. From the 160 abstracts submitted, 108 junior scientists from 23 countries were invited to participate.

In addition to the three recurring topics – molecular neuropsychopharmacology, behavioural pharmacology and clinical neuropsychopharmacology – this year's variable topic was neural and cellular networks in the brain, function and dysfunction.

Two Saturday afternoon optional sessions were also organised: on giving effective talks and writing effective papers, presented by Celso Arango, (Spain); and on jobs in academia and industry and the Innovative Medicines Initiative, presented by Brian Morris (United Kingdom) and Will Spooren (Switzerland).

Sixteen junior scientists, selected on the basis of the quality of their posters, were invited to speak at the 27th ECNP Congress on 18-21 October 2014 in Berlin, Germany.

On 6-11 April 2014, the second edition of **ECNP School on Child and Adolescent Neuropsychopharmacology** was held in Venice, Italy, led by Alessandro Zuddas. Forty-eight young child and adolescent psychiatrist from 28 European countries attended, with a faculty of 18.

The school continued its mission to create a consistent, evidence-based framework for the treatment of children and adolescents with a psychiatric disorder. Its five-day program included 18 plenary lectures on the use of medication in psychiatric disorders with an onset in childhood and adolescence, nine workshops in which complex clinical cases or specific hot topics were discussed, a debate session on the role of medications as first-line treatment, and a practical plenary session on how to prepare an effective presentation.

Feedback was overwhelmingly positive: participants found it an inspiring learning experience, appreciating especially the intense, active interaction with faculty.

The 5th **ECNP School of Neuropsychopharmacology** was held on 29 June-04 July, in Oxford, United Kingdom, led by Guy Goodwin. The school offered participants a week-long programme of intensive training in all aspects of neuropsychopharmacology: from its fundamentals to the use of medications in individual indications, good clinical practice and optimal treatment and algorithms.

This year, 42 psychiatrists from 24 countries were selected, the majority clinicians at university hospitals. A faculty of 15 top scientists volunteered their time to teach and train participants. The post-meeting survey showed a very high level of satisfaction with the scientific and educational standard and the relevance of the information presented.

Building research infrastructure

- **ECNP Networks** – common European clinical databases for research into the main psychiatric conditions. The Networks were launched in 2007 to address the lack of a European research network with access to a common database, a widely recognised shortcoming in Europe's neuropsychopharmacological research infrastructure. The co-operation that the Networks have fostered at the scientific, technical and clinical level has already yielded significant research and public health dividends.

The aims of the ECNP Networks are to:

- Foster multicentre European collaboration in order to collect in a standardised way the essential clinical, psychological, biological and therapeutics variables to be analysed in clinical studies and pharmacological trials.
- Create and foster European networks of highly qualified investigators.
- Provide a platform for collaboration on the development of common assessments and new or follow-up projects

The Networks board comprises of a chair (Celso Arango, Spain) and a scientific co-ordinator (Nic van der Wee, the Netherlands). The board along with the chair and co-chair of each Network forms the Networks Taskforce. Taskforce meets annually and facilitates the

development of new proposals, fosters interaction between networks, and monitors progress and the appropriate use of funding.

- **Nomenclature Project** – a collaborative project to rationalise and improve the nomenclature of psychotropic drugs, in conjunction with the American College of Neuropsychopharmacology (ACNP), International College of Neuropsychopharmacology (CINP), Asian College of Neuropsychopharmacology (AsCNP) and International Union of Basic and Clinical Pharmacology (IUPHAR). The Nomenclature project was established in 2010 to address the disconnect between the nomenclature of psychotropic drugs and the underlying neuroscience of these compounds.



The driver behind the project was the concern that inadequate nomenclature not only made it more difficult to identify – and gain approval for – innovative treatments, but was confusing patients and exacerbating non-compliance, in both cases to the ultimate detriment of patient welfare.

New in 2014

In 2014 ten **ECNP Networks** were active:

- Anxiety Disorders Network (ADRN)
- Bipolar Disorders Network (ENBREC)
- Brain Imaging
- Child and Adolescent Neuropsychopharmacology Network
- Experimental Medicines Network
- Neuroimaging Network
- Obsessive Compulsive and Related Disorders Network (OCRN)
- Preclinical Data Forum
- Suicide Network
- Traumatic Stress Network

In 2014 the Network Board met by teleconferences twice a month. A Network Taskforce meeting was organised in Brussels in March. Nic van der Wee, the scientific co-ordinator, also set up individual meetings with all the chairs and co-chairs of the Networks during the 27th ECNP Congress in October 2014 in Berlin, Germany.

The **Nomenclature Project** saw two major milestones with the public launch of the new nomenclature, encompassing 109 compounds, at the 27th ECNP Congress, 18-21 October 2014, in Berlin, Germany. Five thousand *Neuroscience-based Nomenclature (NbN)* handbooks, published by Cambridge University Press, were distributed free of charge to clinicians around Europe. The handbook was accompanied by a fully searchable app, released free to download in Apple and Google formats.

Translations are now planned for Spanish and Japanese, and an extension of the nomenclature into neurological disorders, as well as a specialised edition for child and adolescent disorders.

Fostering common regional standards

- **Seminars** – interactive training courses for future leading scientists in applied neuroscience, focused every year on a European country whose researchers and practitioners have limited opportunities to attend international meetings.

Around 50 participants attend, selected on the basis of their curriculum vitae and a short abstract (50-100 words describing research or a relevant case). Outstanding participants of the Seminar (max. 5) are awarded free registration and a subsidy towards travel cost for the succeeding ECNP Congress on the condition that they submit an abstract for poster presentation and that the abstract is accepted. R&S covers all costs; participants are asked only to pay their own in-country travel expenses.

- **Supported talks** – ECNP sponsors a variety of talks and symposia at national and international meetings:
 - ECNP-supported talks
 - Mini-Symposia
 - Expert roundtables

New in 2014

In 2014 five **ECNP Seminars** were organised:

- Berovo, Republic of Macedonia, 4-6 April – 42 participants. ECNP experts were Wim van den Brink, the Netherlands, on drug addiction; Gil Zalsman, Israel, on suicide; and Francesc Colom, Spain, on bipolar disorders. Two additional talks were given by Joseph Zohar on how to prepare and publish clinical research project and how to prepare a scientific presentation. On the Saturday afternoon and Sunday morning participants were split into three working groups, organised with the assistance of local experts Kadri Hadzihamza, Mirjana Savevska, and Pavlina Ilievska-Koteska. Three participants received a Seminar Award, which includes free registration and a subsidy towards travel costs for the 27th ECNP Congress in Berlin: Gordana Ristevska-Dimitrovska, Macedonia; Desanka Gjorgevikj, Macedonia; and Marya Stoyanova, Bulgaria.
- Tsaghkadzor, Armenia, 10-12 October – 31 participants. ECNP experts were Gil Zalsman, Israel, on studying gene X environment in affective disorders as a model for research design in psychoneuropharmacology; Avi Avital, Israel, on how to plan a research study; and Carmen Moreno, Spain, on new approaches to the treatment of psychosis and clinical pharmacology of antipsychotics. The two additional practical talks were given by Gil Zalsman. Workshops were organised with the assistance of local experts Armen Melik-Pashayan, Maruke Eghiyanyan and Artur Mkrtchyan. Five participants were chosen for the Seminar Award: Narine Israelian, Artavazd Manvelyan, Katsiaryna Mironava, Narine Nersisyan and Karine Tadevosyan.
- Istanbul, Turkey, 14-16 November – 43 participants. ECNP Experts were Naomi Fineberg, UK, on OCD state of the art in treatment; Wim van den Brink, Netherlands, on drug addiction research as a model for research plans and design; and Michael Davidson, Israel, on negative and cognitive symptoms in schizophrenia. Two additional talks were given by Wim van den Brink. Three workshops were organised with the assistance of local experts Oguz

Karamustafalioglu, Aysegul Yildiz, and Koksal Alpetekin. Five participants received a Seminar Award: Zumrut Duygu Sen, Mehmet Diyaddin Guleken, Halide Bilge Turkozer, Burc Aydin and Gokben Hizli Sayar.

- Ecka, Serbia, 14-16 November – 30 participants. ECNP Experts were Gil Zalsman, Israel, on the suicidal patient-risk assessment and prevention; Dina Popovic, Spain, on the maintenance treatment of bipolar disorder- focus on the polarity index; and Robin Jacoby, United Kingdom, on the management of depressive illness in old age. Two additional talks were given by Gil Zalsman. Three workshops were organised with the assistance of local experts, Tamara Cavic, Janko Samardzic, and Dejan Stevanovic. Five participants received a Seminar Award: Timic Stamenic Tamara, Kostic Milutin, Poznic Jesic Milana, Mitkovic Voncina Marija, and Dunjic Kostic Bojana.
- Napareuli, Georgia, 28-30 November – 47 participants. ECNP Experts were Joseph Zohar, Israel, on science and nomenclature and an updates on changes to an outdated psychotropic classification; Francesc Colom, Spain, on clinical and therapeutic updates on bipolar disorder; and Michael Davidson, Israel, on how to interpret results of published trials using treatment resistant schizophrenia as an example. In addition two talks were given by Joseph Zohar. Three workshops were organised with the assistance of local experts Nino Okribelashvili, Manana Bokuchava and Eka Chkonია. Five participants received a Seminar Award: Maka Malania, Cezar Goletiani, Ia Adamia, Eka Berdzenishvili and Tamar Aladashvili.

The year also saw two successful **ECNP Supported Talks**, furthering the goal of this programme to facilitate the diffusion of cutting-edge research and clinical practice in a simple, easy-to-organise and high-impact format:

- Michael Davidson, 'Randomness and causality in psychiatric clinical practice and research' 4th Young Psychiatrists' Network Meeting, Wroclaw, Poland, 4 April
- Stuart Montgomery, 'The implications of the cultural factors in the assessment of the Major Depression' Romanian Association of Psychiatry and Psychotherapy, Sinaia, Romania, 9 October

R&S supports the travel costs, including air fare (economy class), hotel accommodation and public transport, up to a fixed amount.

5. Forward Strategy

Risk Management and Long-Term Financial Strategy

The income of R&S derives in part from the proceeds of the ECNP Congress, in those years in which the congress achieves a surplus. The congress, in turn, derives its incomes from three main sources: (1) registration fees, (2) industry exhibition fees, and (3) industry satellite symposia fees. No other support is allowed.

It has long been the expectation that participation in the congress by the pharmaceutical industry will decrease over time, as the economics of the pharma industry change and the regulations governing the support it is able to provide for continuing medical education (CME) becomes more restrictive.

The foundation has been preparing itself for the eventuality of industry support in the congress – and hence congress donations to R&S – decreasing altogether, and R&S being wholly dependent on its own accumulated resources to continue its many scientific and educational activities. The unpredictable nature of the time horizon in which this will occur, however, makes financial forecasting for the foundation challenging.

Moreover, the volatility in the financial markets since the beginning of the financial crisis in 2008 has made R&S's other source of income – investment earnings – also highly unstable. The significant uncertainty it has introduced, has made accurate budgeting and forward planning difficult.

Future Spending Plans

In order to prevent excess capital accumulation, spending plans have been developed to run a persistent budget deficit.

Extensions of the current budgetary provisions have been planned to encompass these programmes:

- Neuroscience Summer School, in collaboration with the European Neuroscience Schools Programme
- Brain Prize Master Class
- Psychotherapy and Neuroscience Meeting, Nice, France – and subsequent thematic 'incubator' meetings
- Expansion of the e-learning programme
- Expansion of the ECNP Networks initiative
- Clinical Trials Platform
- Cost and prevalence studies

It should be noted that, built into this schema, is the possibility to expand, add or remove activities depending on income fluctuations.

	2014	2015	2016	2017	2018	2019
EXPENSES						
Develop young researchers						
Workshop	143.053	160.000	173.000	176.000	180.000	184.000
Internship Programme	0	20.000	21.000	2.000	23.000	24.000
Research Methodology Workshop	–	60.000	61.500	63.000	64.500	66.000
ECNP Schools	153.928	265.000	170.000	270.000	173.000	275.500
Brain Prize Masterclass	–	–	30.000	30.600	31.200	31.800
Neuroscience Summer School	–	–	100.000	102.000	104.000	106.000
E-learning	0	20.000	50.000	51.000	52.000	53.000
Build infrastructure						
ECNP Networks	39.546	100.000	150.000	153.000	156.000	160.000
Nomenclature Project	132.303	80.000	81.600	83.200	85.000	86.700
Clinical Trials Platform	–	–	75.000	83.000	90.000	98.000
Facilitate dialogue						
Incubator Meeting, Nice	0	50.000	100.000	102.000	104.000	106.000
ECNP Summit / Collaborative Forum	0	–	–	–	–	–
ISCTM	0	0	10.000	10.200	10.400	10.600
Raise Awareness						
Cost and prevalence studies	0	0	100.000	102.000	104.400	107.000
Foster common regional standards						
Seminars (x6)	73.698	90.000	92.000	94.000	96.000	98.000
Supported talks	2.654	15.000	50.000	51.000	52.000	53.000
Other expenses						
ECNP Office	224.358	225.000	230.000	235.000	240.000	245.000
Sundry/miscellaneous	1.464	42.000	50.000	52.000	54.000	56.000
Audit and tax fees	0	25.000	25.500	26.000	26.600	27.500
Bank charges and commission charges	0	20.000	21.000	22.000	23.000	24.000
Total expenses	771.004	1.172.000	1.590.600	1.708.000	1.669.100	1.812.000
INCOME						
Congress (3.291.199)	1.168.965	650.000	700.000	700.000	700.000	700.000
Interest and similar income	614.016	300.000	350.000	350.000	350.000	350.000

	2014	2015	2016	2017	2018	2019
Total income	1.782.981	950.000	1.050.000	1.050.000	1.050.000	1.050.000
NET RESULT	1.011.977	-222.000	-540.600	-658.000	-619.100	-762.100

6. Finances

Balance sheet as at 31 December 2014

	31-12-2014		31-12-2013	
	€	€	€	€
ASSETS				
CURRENT ASSETS				
Accounts receivable				
Debtors		8,698		0
Amounts owed by congress foundations		259,828		512,453
Taxes		10,091		36,574
Other receivables		138,722		120,708
Payments and accrued income		123,220		145,255
		540,559		814,990
Securities		8,192,248		7,600,005
Bank deposits		4,650,703		3,888,426
		<u>13,383,510</u>		<u>12,303,421</u>
EQUITY AND LIABILITIES				
EQUITY CAPITAL				
Brought forward from last year		12,043,301		10,694,874
Result 2014 (2013)		1,011,977		1,348,427
		13,055,278		12,043,301
CURRENT LIABILITIES				
Trade creditors		115,127		48,035
Accounts owed to congress foundations		2,589		0
Accounts owed to other foundations and ECNP		211,464		
Other liabilities		-948		621
		328,232		260,120
		<u>13,383,510</u>		<u>12,303,421</u>

Profit and loss account 2014

	<u>Balance 2014</u>	<u>Balance 2013</u>
	€	€
INCOME		
Proceeds fundraising	1,169,381	1,759,230
Legal fees congress foundations	-416	-21,382
Interest and similar income	614,016	230,899
Total income	<u>1,782,981</u>	<u>1,968,747</u>
EXPENSES		
Meetings and other activities	546,646	421,554
Other expenses	224,358	198,766
Total expenses	<u>771,004</u>	<u>620,320</u>
NET RESULT	<u>1,011,977</u>	<u>1,348,427</u>
Appropriation of result		
Result 2014 (2013)	<u>1,011,977</u>	<u>1,348,427</u>



© ECNP 2015

Bolognalaan 28
3584 CJ
The Netherlands

www.ecnp.eu

ECNP is a public-interest-serving entity (algemeen nut beogende instelling – ANBI) under Dutch tax law